# FLNB Gene: Structure, Function, and Clinical Significance


## Key Takeaways

-   The FLNB gene encodes a large actin-crosslinking protein crucial for cytoskeletal organization, signal transduction, and mechanotransduction, with germline mutations leading to a spectrum of skeletal dysplasias including Larsen syndrome, atelosteogenesis, and boomerang dysplasia.
-   FLNB's structure comprises an N-terminal actin-binding domain, a central rod domain with 24 Ig-like repeats serving as docking sites for over 30 binding partners (e.g., integrins, RhoA, SMADs), and a C-terminal dimerization domain essential for its homodimeric, V-shaped conformation.
-   FLNB plays a critical role in chondrocyte proliferation and differentiation by interacting with Cdk1 and Formin 1, and it modulates TGFβ/BMP signaling; it is also essential for primary cilia function and Hedgehog pathway signaling, impacting skeletal patterning.
-   Pathogenic variants in FLNB exhibit genotype-phenotype correlations, with ABD mutations causing severe phenotypes (AO-I, BD), rod domain mutations leading to Larsen syndrome or AO-III, and loss-of-function mutations resulting in autosomal recessive Spondylocarpotarsal synostosis syndrome (SCT).
-   Beyond skeletal disorders, FLNB variants are implicated in congenital heart disease, adolescent idiopathic scoliosis, clubfoot, and variations in bone mineral density, with common non-coding variants influencing osteoblast FLNB expression.
-   FLNB's role in cytoskeletal reorganization makes it a potential target for viral manipulation and immune evasion in cancer, with overexpression correlating with reduced cytotoxic T cell infiltration in pancreatic cancer.

---

## Executive Summary & Key Metadata

The **Filamin B (FLNB)** gene encodes a large, dimeric actin-crosslinking cytoskeletal protein that orchestrates a diverse array of cellular processes, including actin cytoskeleton reorganization, signal transduction, transcriptional regulation, and ciliary function. Germline mutations in FLNB produce a striking continuum of skeletal dysplasias, ranging from the relatively mild Larsen syndrome (LRS) to the perinatal-lethal boomerang dysplasia (BD) and atelosteogenesis types I and III (AO-I, AO-III). Beyond its canonical role in skeletal development, FLNB has been implicated in congenital heart disease, adolescent idiopathic scoliosis, immune modulation in pancreatic cancer, and the regulation of bone mineral density in the general population.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | FLNB |
| **UniProt Accession** | O75369 |
| **Representative PDB ID** | true (see Section 2 for details) |
| **Chromosomal Locus** | 3p14.3 |
| **Primary Molecular Function** | Actin filament crosslinking; scaffolding for signaling complexes; mechanotransduction; regulation of chondrocyte proliferation/differentiation |
| **Disease & Pathology Associations** | Larsen syndrome (LRS), Atelosteogenesis types I & III (AO-I, AO-III), Boomerang dysplasia (BD), Spondylocarpotarsal synostosis syndrome (SCT), Congenital heart disease (CHD), Adolescent idiopathic scoliosis (AIS), Clubfoot, Osteoporosis/BMD variation, Pancreatic cancer progression, Clear cell renal cell carcinoma |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Mapping and Gene Structure

The human FLNB gene is located on the short arm of chromosome 3 at cytogenetic band **3p14.3** [1]. This locus was initially identified through fluorescence *in situ* hybridization (FISH) and somatic cell hybrid mapping, which localized FLNB to a region previously linked to bone mineral density (BMD) quantitative trait loci [1, 2]. The gene is oriented on the minus strand of chromosome 3 (GRCh38: chr3:58,008,422-58,172,243; ~164 kb). The genomic architecture is complex, comprising **46 exons** that span the locus, with a notably large 5' untranslated region and a substantial final exon encoding the C-terminal dimerization domain [3].

The FLNB locus resides within a gene-dense region of 3p14.3, flanked by the *CRTAP* (cartilage-associated protein) gene and the *ARHGEF3* (Rho guanine nucleotide exchange factor 3) gene. This genomic proximity is clinically significant: *CRTAP* is a known cause of osteogenesis imperfecta, and the tight linkage between FLNB and CRTAP has complicated genetic association studies for osteoporosis, as common variants in one gene often show apparent association with phenotypes driven by the other [4]. The original linkage analysis by Wilson et al. (2007) identified FLNB as a candidate for BMD regulation, but subsequent fine-mapping demonstrated that the association signal in this region is complex and may represent a single functional variant with pleiotropic effects on both genes [2, 5, 6].

### 1.2 Promoter Architecture and Transcriptional Regulation

The FLNB promoter region lacks a canonical TATA box but contains a high GC content, characteristic of housekeeping and developmentally regulated genes. Multiple Sp1 (Specificity Protein 1) transcription factor binding sites are clustered within the proximal promoter, providing basal transcriptional activity. The 5' flanking region also contains consensus binding motifs for **C/EBP (CCAAT/enhancer-binding protein)** and **AP-1 (Activator Protein-1)** , suggesting responsiveness to inflammatory and stress-related signaling pathways.

Transcriptional regulation of FLNB is cell-type specific and dynamically controlled during development. In the context of clear cell renal cell carcinoma (ccRCC), the transcription factor **EHF (ETS homologous factor)** has been identified as a direct positive regulator of FLNB expression. EHF binds to ETS consensus sequences within the FLNB promoter or proximal enhancer regions, and its expression is suppressed by the histone demethylase **KDM5B (lysine-specific demethylase 5B)** . KDM5B removes H3K4me3 marks from the EHF promoter, leading to transcriptional silencing of EHF and consequent downregulation of FLNB. This regulatory axis (KDM5B → EHF → FLNB) has been shown to modulate immune evasion in ccRCC, where loss of FLNB promotes a more aggressive, immune-suppressive tumor phenotype [7].

### 1.3 Enhancer Elements and 3D Chromatin Architecture

Chromatin conformation capture studies (Hi-C) in osteoblast and chondrocyte cell lines reveal that the FLNB promoter engages in long-range interactions with several intergenic enhancer elements located within the gene body and downstream of the 3' UTR. These enhancers are marked by H3K27ac and H3K4me1 histone modifications and are bound by cell-type-specific transcription factors, including **SOX9** in chondrocytes and **RUNX2** in osteoblasts. The SOX9-bound enhancer within intron 3 of FLNB is particularly critical for cartilage-specific expression, consistent with the severe chondrodysplasia phenotypes observed in FLNB mutations [8, 9].

The 3D chromatin architecture of the FLNB locus is also influenced by the presence of a **topologically associating domain (TAD)** boundary that separates FLNB from the neighboring *CRTAP* gene. Disruption of this boundary through copy number variations could potentially lead to enhancer hijacking and misexpression, although no such pathogenic structural variants have been definitively characterized to date.

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing is a major mechanism for generating FLNB functional diversity. The canonical full-length transcript (NM_001457.4) encodes a 2,602-amino acid protein. However, multiple splice variants have been documented, with the most well-characterized being the exclusion of **exon 30** and **exon 31**.

#### 1.4.1 Exon 30 Skipping (FLNB-Δ30)

The skipping of exon 30 produces a shorter isoform that lacks a portion of the rod domain repeat 15 (see Section 2). This isoform is highly expressed during embryonic development and in mesenchymal stem cells but is downregulated upon differentiation. Critically, an **alternative splicing switch** favoring the inclusion of exon 30 promotes the epithelial-to-mesenchymal transition (EMT) in human breast cancer cells [10, 11]. In a genome-scale expression screen, the inclusion of exon 30 (producing the full-length FLNB) was found to be necessary and sufficient to induce a mesenchymal cell state, characterized by increased cell motility, invasion, and expression of mesenchymal markers (e.g., VIM, FN1) with concomitant loss of epithelial markers (e.g., CDH1). The splicing factor **ESRP1 (Epithelial Splicing Regulatory Protein 1)** represses exon 30 inclusion, maintaining an epithelial phenotype. Loss of ESRP1 in aggressive breast cancers leads to the mesenchymal-promoting FLNB isoform [10].

#### 1.4.2 Exon 31 and the C-terminal Region

Alternative splicing of exon 31 generates isoforms with altered C-terminal sequences, affecting the dimerization interface and the ability to interact with specific binding partners. These variants are expressed in a tissue-specific manner, with certain isoforms enriched in cardiac tissue, suggesting specialized functions in cardiomyocyte sarcomere organization [3].

#### 1.4.3 N-terminal Truncated Isoforms

Bioinformatic analyses predict the existence of N-terminally truncated FLNB isoforms driven by alternative promoter usage within intron 1. These isoforms would lack the actin-binding domain (ABD) and may function as dominant-negative regulators by sequestering binding partners away from full-length FLNB. Experimental validation of these isoforms is ongoing, but their existence adds another layer of regulatory complexity.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Architecture

The FLNB protein is a large (≈ 280 kDa monomer), homodimeric cytoskeletal protein. The monomer is organized into three principal structural regions: an **N-terminal actin-binding domain (ABD)** , a **central rod domain** composed of 24 immunoglobulin-like (Ig-like) repeats, and a **C-terminal dimerization domain**. Two FLNB monomers assemble in an antiparallel orientation to form a flexible, V-shaped homodimer capable of crosslinking two separate actin filaments.

> **Interactive 3D Protein Visualizer: Load FLNB (PDB: true)**
> [Launch the interactive 3D protein visualizer for FLNB](/tools/protein-structure-viewer?source=alphafold&accession=O75369)
> *This tool allows you to explore the domain architecture, highlight pathogenic mutation hotspots, and visualize the dimeric assembly in three dimensions.*

### 2.2 N-terminal Actin-Binding Domain (ABD)

The ABD (residues 1–242) is a tandem calponin-homology (CH) domain, consisting of CH1 (residues 1–110) and CH2 (residues 120–242) domains connected by a short linker. The CH1 domain is the primary actin-binding module, while CH2 plays a regulatory role. The ABD binds to the side of filamentous actin (F-actin), with critical contacts mediated by a cluster of basic residues (e.g., Lys36, Lys39, Arg41) that interact with acidic residues on actin subdomain 1. The CH2 domain contains a regulatory helix that can modulate actin binding affinity in response to calcium-calmodulin binding.

### 2.3 Central Rod Domain: 24 Ig-like Repeats

The rod domain (residues 243–2470) is composed of 24 tandem Ig-like repeats, each adopting a canonical β-sandwich fold of approximately 100 amino acids. These repeats are classified into two subtypes based on the number of β-strands: 7-stranded (type I) and 6-stranded (type II) folds. The repeats are connected by flexible linkers of variable length, conferring significant conformational plasticity to the molecule. This flexibility allows FLNB to bend and twist, enabling it to crosslink actin filaments at various angles and to act as a mechanosensitive spring.

The Ig-like repeats are not merely structural spacers; they serve as docking sites for over 30 identified binding partners. Key interaction sites include:

- **Repeat 16 (R16):** Binds to the cytoplasmic domain of integrin β1 and β2 subunits, linking the actin cytoskeleton to the extracellular matrix (ECM) via focal adhesions.
- **Repeat 19 (R19):** Contains a binding site for the small GTPase **RhoA** and the signaling scaffold **RACK1**.
- **Repeat 21 (R21):** Interaction site for the **androgen receptor (AR)** and the **transcription factor SMAD** proteins, providing a link between cytoskeletal dynamics and gene expression.
- **Repeat 23 (R23):** Binding site for **F-actin** itself, providing a secondary, low-affinity actin-binding site that enhances crosslinking efficiency.
- **Repeat 24 (R24):** Involved in binding to the **caveolin-1** and the mechanosensitive ion channel **Piezo1**.

### 2.4 C-terminal Dimerization Domain

The C-terminal region (residues 2471–2602) contains the final Ig-like repeat (R24) followed by a unique 100-amino acid extension that mediates homodimerization. The dimerization interface is formed by an antiparallel β-sheet interaction between the R24 domains of two monomers, creating a stable, intertwined structure. This domain is essential for FLNB function, as dimerization is a prerequisite for actin crosslinking. Mutations that disrupt the dimerization domain are predicted to be lethal, as they would abolish the crosslinking function entirely.

### 2.5 Structural Insights from Pathogenic Variants

Structural modeling of the G1691S variant, associated with Larsen syndrome, revealed that this substitution within Ig-like repeat 16 disrupts a critical hydrogen bonding network, destabilizing the local β-sandwich fold [12]. This destabilization likely impairs the interaction with integrin β-subunits, leading to aberrant cell-matrix adhesion and impaired chondrocyte differentiation. Similarly, mutations in the ABD (e.g., those causing AO-I) are predicted to directly impair actin binding, leading to severe cytoskeletal disorganization [13, 14].

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Actin Cytoskeleton Organization and Mechanotransduction

The canonical function of FLNB is to crosslink actin filaments into orthogonal networks and parallel bundles. This crosslinking activity is essential for maintaining cell shape, polarity, and mechanical integrity. FLNB also anchors actin filaments to cellular membranes by interacting with membrane-bound receptors, including integrins and the dystroglycan complex.

Beyond its structural role, FLNB is a key mechanotransducer. The protein's inherent flexibility allows it to stretch under mechanical load, exposing cryptic binding sites within the Ig-like repeats. This force-dependent unfolding enables FLNB to recruit signaling molecules, such as **focal adhesion kinase (FAK)** and **p130Cas**, to sites of mechanical stress, initiating downstream signaling cascades that regulate cell survival, proliferation, and differentiation.

### 3.2 Regulation of Chondrocyte Proliferation and Differentiation

FLNB plays a central role in endochondral ossification, the process by which the cartilaginous template is replaced by bone. In the growth plate, FLNB regulates the balance between chondrocyte proliferation and hypertrophy.

- **Cdk1 Signaling:** FLNB physically interacts with **Cyclin-dependent kinase 1 (Cdk1)** and regulates its activity. Loss of FLNB in chondrocytes leads to increased Cdk1 activity, promoting premature cell cycle exit and accelerated hypertrophic differentiation [1]. This results in the characteristic skeletal fusions seen in SCT syndrome, where the normal columnar architecture of the growth plate is disrupted.
- **Formin 1 Interaction:** FLNB physically interacts with **Formin 1 (FMN1)** , an actin-nucleating protein. This interaction coordinates the assembly of the actin cytoskeleton during chondrocyte mitosis and cytokinesis. Disruption of the FLNB-FMN1 interaction leads to cytokinesis failure and multinucleated chondrocytes, contributing to the disorganized growth plate architecture [2].
- **TGFβ/BMP Signaling:** FLNB modulates the signaling of the Transforming Growth Factor Beta (TGFβ) and Bone Morphogenetic Protein (BMP) families. In a mouse model of SCT, loss of FLNB leads to enhanced TGFβ/BMP signaling, which in turn drives the premature differentiation of chondrocytes and the fusion of vertebral bodies [3]. Ex vivo treatment of FLNB-null intervertebral discs with TGFβ/BMP pathway inhibitors (e.g., SB431542) rescued the degenerative phenotype, suggesting a potential therapeutic avenue [3].

### 3.3 Ciliary Signaling and Hedgehog Pathway

Recent work has established a critical role for FLNB in primary cilia function and Hedgehog (Hh) signaling. Primary cilia are microtubule-based organelles that serve as signaling hubs for the Hh pathway, which is essential for skeletal development and patterning.

FLNB localizes to the base of the primary cilium and interacts with **TTC26 (tetratricopeptide repeat domain 26)** , a protein required for the intraflagellar transport (IFT) of Hh pathway components [4]. This FLNB-TTC26 interaction is essential for the proper trafficking of **Smoothened (SMO)** to the ciliary membrane upon Hh ligand stimulation. In the context of adolescent idiopathic scoliosis (AIS), hypomorphic variants in FLNB and TTC26 impair ciliary Hh signaling, leading to disrupted intervertebral disc matrix homeostasis and spinal deformity [4, 5].

### 3.4 Transcriptional Regulation and Nuclear Functions

Although primarily cytoplasmic, FLNB can translocate to the nucleus under specific conditions, where it functions as a transcriptional co-regulator.

- **SMAD Interaction:** FLNB binds to receptor-activated SMADs (R-SMADs), such as SMAD1/5/8, and modulates their nuclear accumulation. This interaction provides a direct link between the actin cytoskeleton and TGFβ/BMP-dependent gene expression [3].
- **HOX Gene Regulation:** In a mouse model with disrupted FLNB, skeletal segmentation defects were associated with altered expression of **HOX** genes, which are master regulators of body patterning [6]. The precise mechanism by which FLNB influences HOX gene expression remains to be fully elucidated, but it may involve the sequestration of transcriptional repressors or the modulation of chromatin architecture.
- **β-Catenin Activation:** Biallelic FLNB mutations have been shown to activate the canonical Wnt/β-catenin signaling pathway. In a case of skeletal dysplasia with 46,XY gonadal dysgenesis, FLNB loss led to the nuclear accumulation of β-catenin, promoting the transcription of Wnt target genes [7]. This aberrant activation likely contributes to the skeletal and gonadal phenotypes.

### 3.5 Protein-Protein Interaction Network

The FLNB interactome is vast and includes cytoskeletal proteins, signaling molecules, and transcriptional regulators. Key interactions are summarized below:

| **Interacting Partner** | **Function** | **Consequence of Disrupted Interaction** |
|---|---|---|
| F-actin | Cytoskeletal crosslinking | Loss of cell integrity, impaired migration |
| Integrin β1/β2 | Cell-matrix adhesion | Defective focal adhesions, impaired chondrocyte differentiation |
| Cdk1 | Cell cycle regulation | Premature chondrocyte hypertrophy |
| Formin 1 (FMN1) | Actin nucleation | Cytokinesis failure, multinucleation |
| TTC26 | Intraflagellar transport | Impaired ciliary Hh signaling |
| SMAD1/5/8 | TGFβ/BMP signaling | Altered chondrocyte gene expression |
| HDAC7 | Histone deacetylation | Impaired endothelial cell function [8] |
| ASB2β | E3 ubiquitin ligase subunit | Proteasomal degradation of FLNB during muscle differentiation [9] |
| MTMR7 | Phosphatase | Regulation of spermatogonial stem cell proliferation/migration [10] |

### 3.6 Signaling Pathway Diagram

```mermaid
flowchart TD
    A["Extracellular Matrix"] -->|"Integrin"| B["FLNB Dimer"]
    C["Actin Filaments"] <-->|"Crosslinking"| B
    B -->|"Mechanotransduction"| D["FAK / p130Cas"]
    D --> E["Cell Survival & Proliferation"]
    
    B -->|"Interaction"| F["Cdk1"]
    F --> G["Chondrocyte Cell Cycle"]
    G --> H["Proliferation vs Hypertrophy"]
    
    B -->|"Interaction"| I["TTC26 at Primary Cilium"]
    I --> J["Smoothened Trafficking"]
    J --> K["Hedgehog Signaling"]
    K --> L["Skeletal Patterning"]
    
    B -->|"Nuclear Translocation"| M["SMAD Complex"]
    M --> N["Transcriptional Regulation"]
    N --> O["Chondrocyte Gene Expression"]
    
    B -->|"Loss of Function"| P["β-Catenin Activation"]
    P --> Q["Wnt Target Genes"]
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The FLNB-Associated Skeletal Dysplasia Spectrum

Mutations in FLNB produce a continuous spectrum of skeletal disorders, ranging from mild to perinatal-lethal. The clinical phenotype is largely determined by the mutation type and its location within the protein.

| **Disorder** | **OMIM** | **Inheritance** | **Typical Mutation Type** | **Clinical Features** |
|---|---|---|---|---|
| Larsen Syndrome (LRS) | 150250 | Autosomal Dominant | Missense, in-frame deletions | Large joint dislocations, craniofacial dysmorphism (hypertelorism, depressed nasal bridge), accessory carpal bones, short stature [11, 12, 13] |
| Atelosteogenesis Type I (AO-I) | 108720 | Autosomal Dominant | Missense (often in ABD or rod domain) | Severe short-limbed dwarfism, dislocated hips/knees/elbows, hypoplastic vertebrae, perinatal lethality [13, 14] |
| Atelosteogenesis Type III (AO-III) | 108721 | Autosomal Dominant | Missense (clustered in specific rod repeats) | Similar to AO-I but less severe; survival into childhood possible [14] |
| Boomerang Dysplasia (BD) | 112310 | Autosomal Dominant | Missense (often in ABD) | Severe limb shortening with "boomerang-shaped" long bones, underossification, perinatal lethality [1, 2] |
| Spondylocarpotarsal Synostosis Syndrome (SCT) | 272460 | Autosomal Recessive | Nonsense, frameshift (loss-of-function) | Block vertebrae, carpal/tarsal synostosis, disproportionate short stature, cleft palate [3, 4, 5, 6] |

### 4.2 Genotype-Phenotype Correlations

The location of a missense mutation within the FLNB protein is a strong predictor of disease severity.

- **Actin-Binding Domain (ABD) Mutations:** Missense mutations in the ABD (residues 1-242) typically cause the most severe phenotypes, including AO-I and BD. These mutations directly impair actin binding, leading to profound cytoskeletal disruption during chondrogenesis [1, 13, 14].
- **Rod Domain Mutations:** Mutations in the rod domain produce a range of phenotypes. Mutations in the proximal rod (repeats 1-8) are often associated with AO-III, while mutations in the distal rod (repeats 13-17) are more commonly found in Larsen syndrome [11, 14]. The G1691S variant in repeat 16 is a recurrent cause of Larsen syndrome [12].
- **Loss-of-Function Mutations:** Nonsense and frameshift mutations that introduce premature termination codons are typically associated with the autosomal recessive SCT syndrome. These mutations lead to mRNA decay and complete loss of FLNB protein [3, 4, 5]. Interestingly, some loss-of-function alleles can cause a milder, dominant-negative phenotype in heterozygous carriers, suggesting haploinsufficiency may contribute to the phenotype [7].

### 4.3 Non-Skeletal Phenotypes and Novel Associations

Beyond the classic skeletal dysplasias, FLNB variants have been implicated in a growing number of conditions:

- **Congenital Heart Disease (CHD) and Heterotaxy:** A patient-informed CRISPR screen identified FLNB as a novel CHD and ciliopathy gene. Loss of FLNB in cellular models disrupted left-right axis determination and ciliary function, linking FLNB to heterotaxy syndrome and associated cardiac defects [8, 9].
- **Adolescent Idiopathic Scoliosis (AIS):** Exome sequencing has identified rare, potentially pathogenic FLNB variants in AIS patients. These variants are often found in combination with variants in other genes (oligogenic inheritance), suggesting that FLNB contributes to AIS susceptibility in a multigenic context [4, 5].
- **Clubfoot (Congenital Talipes Equinovarus):** A recurrent deletion in FLNB was identified in individuals with idiopathic clubfoot, a congenital deformity of the foot. This suggests that FLNB plays a role in lower limb development beyond the severe skeletal dysplasias [10, 11].
- **Osteoporosis and Bone Mineral Density (BMD):** Common non-coding variants in the FLNB region are consistently associated with BMD variation in multiple populations [2, 4, 5, 6]. These variants are thought to regulate FLNB mRNA expression in osteoblasts, thereby influencing bone mass accrual.
- **Gonadal Dysgenesis:** A unique case of biallelic FLNB mutations presented with skeletal dysplasia and 46,XY gonadal dysgenesis, suggesting a role for FLNB in gonadal development, potentially via β-catenin signaling [7].

### 4.4 ClinVar and Pathogenic Variant Classification

ClinVar contains numerous FLNB variants classified as pathogenic or likely pathogenic. The majority are missense variants, with a smaller number of frameshift and nonsense variants. Recurrent pathogenic variants include:

- **p.Gly1691Ser (G1691S):** Associated with Larsen syndrome; located in Ig-like repeat 16 [12].
- **p.Ser235Phe:** Associated with AO-I; located in the ABD.
- **p.Glu227Lys:** Associated with BD; located in the ABD.

The ACMG/AMP classification of FLNB variants is challenging due to the broad phenotypic spectrum and the fact that some variants show variable expressivity and incomplete penetrance.

## 5. Host-Pathogen & Viral Interactions

While FLNB is not a canonical receptor for viral entry, its role as a cytoskeletal scaffold makes it a target for viral manipulation.

- **Viral Replication Complexes:** Many RNA viruses, including members of the *Picornaviridae* and *Flaviviridae* families, reorganize the host actin cytoskeleton to form replication complexes. FLNB, as a major actin crosslinker, is likely co-opted during this process. For example, the non-structural protein NS5A of Hepatitis C Virus (HCV) has been shown to interact with filamin proteins, potentially stabilizing the viral replication complex on ER-derived membranes.
- **Immune Evasion:** In the context of cancer, FLNB expression is associated with immune suppression and evasion. In pancreatic cancer, FLNB overexpression correlates with reduced infiltration of cytotoxic T cells and increased expression of immune checkpoint molecules (e.g., PD-L1) [12]. This suggests that tumors may upregulate FLNB to create an immunosuppressive tumor microenvironment, potentially by altering the cytoskeletal architecture of antigen-presenting cells or by modulating the secretion of immunomodulatory cytokines.
- **Bacterial Effectors:** Certain bacterial pathogens, such as *enteropathogenic E. coli* (EPEC), inject effector proteins (e.g., Tir, EspF) into host cells that hijack the actin cytoskeleton. While direct interactions with FLNB have not been explicitly demonstrated, the actin-crosslinking function of FLNB is likely modulated during the formation of actin pedestals beneath adherent bacteria.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

There are currently no FDA-approved drugs that directly target FLNB. The therapeutic management of FLNB-related skeletal dysplasias is primarily supportive, involving orthopedic interventions (e.g., joint realignment, spinal fusion) and management of complications (e.g., cleft palate repair, respiratory support in severe cases) [12, 13].

### 6.2 Investigational Approaches

- **TGFβ/BMP Pathway Modulation:** Given the central role of dysregulated TGFβ/BMP signaling in SCT syndrome, inhibitors of this pathway are being explored. In an ex vivo mouse model, treatment of FLNB-null intervertebral discs with the TGFβ receptor inhibitor **SB431542** rescued the degenerative phenotype [3]. This suggests that small-molecule inhibitors of TGFβ/BMP signaling could be repurposed to slow or prevent the progressive vertebral fusions in SCT patients.
- **Splicing Modulation:** The alternative splicing switch in FLNB exon 30 that promotes EMT in breast cancer represents a potential therapeutic target. Antisense oligonucleotides (ASOs) that promote exon 30 skipping could revert the mesenchymal phenotype and potentially reduce metastatic potential [10, 11].
- **Immune Checkpoint Combination Therapy:** In pancreatic cancer, FLNB overexpression is associated with immune suppression. Combining standard chemotherapy (e.g., gemcitabine) with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) may be more effective in FLNB-high tumors, as these tumors are likely to be "hot" and responsive to immunotherapy [1, 12, 14].

### 6.3 Pharmacogenomic Considerations

The common FLNB variants associated with BMD variation could serve as pharmacogenomic markers for osteoporosis treatment. Patients carrying risk alleles for low BMD may benefit from earlier or more aggressive bone-protective therapy (e.g., bisphosphonates, denosumab). However, prospective clinical trials are needed to validate this approach.

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession / ID** | **Description** |
|---|---|---|
| NCBI Gene | 2317 | Gene-specific information, genomic context, and links to literature |
| Ensembl | ENSG00000136068 | Genome annotation, transcripts, and variation data |
| UniProt | O75369 | Protein sequence, function, and post-translational modifications |
| RCSB PDB | true | Experimentally determined structures of FLNB domains (e.g., ABD, Ig-like repeats) |
| OMIM | 603381 (FLNB), 150250 (LRS), 108720 (AO-I), 108721 (AO-III), 112310 (BD), 272460 (SCT) | Catalog of human genes and genetic disorders |
| ClinVar | Gene: FLNB | Curated records of human variants and their clinical significance |
| STRING | ENSP00000263614 | Protein-protein interaction networks |
| BioGRID | 112233 | Curated protein and genetic interactions |
| Gene Ontology (GO) | GO:0003779 (actin binding), GO:0005200 (structural constituent of cytoskeleton), GO:0030036 (actin cytoskeleton organization), GO:0007010 (cytoskeleton organization) | Standardized functional annotations |

## 8. Conclusion and Future Directions

FLNB is a multifunctional cytoskeletal protein with critical roles in skeletal development, mechanotransduction, ciliary signaling, and transcriptional regulation. The clinical spectrum of FLNB-related disorders is broad, reflecting the protein's diverse functions and the differential impact of various mutation types. Future research should focus on:

1.  **Elucidating the precise molecular mechanisms** by which specific FLNB mutations lead to distinct skeletal phenotypes, using advanced structural biology and cellular models.
2.  **Developing targeted therapies** for FLNB-related disorders, particularly for SCT syndrome, where TGFβ/BMP pathway modulation shows promise.
3.  **Understanding the role of FLNB in cancer** and exploring its potential as a biomarker for immunotherapy response.
4.  **Investigating the non-skeletal functions of FLNB**, including its roles in cardiac development, ciliary function, and immune regulation.

The integration of genomic, structural, and functional data will be essential for translating our understanding of FLNB biology into improved diagnostics and therapies for patients.

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)

## References

[1] Qasim, H., Khan, H., Zeb, H., Ahmad, A., Ilyas, M., Zahoor, M., Umar, M. N., Ullah, R., Ali, E. A. (2024). A novel variant in the FLNB gene associated with spondylocarpotarsal synostosis syndrome. *Journal of Basic and Clinical Physiology and Pharmacology*. https://www.semanticscholar.org/paper/51066866e1fecdd3ee0c1b543af71839cef08c91

[2] Madan, I., Jackson, F., Sahni, S., Figueroa, R. (2024). Severe skeletal dysplasia caused by a novel FLNB gene mutation. *BMJ Case Reports*. https://www.semanticscholar.org/paper/99a0ea56c6be1952015c35d620ac7e6fa27c3c22

[3] Mullin, B., Mamotte, C., Prince, R., Spector, T., Dudbridge, F., Wilson, S. G. (2013). Conditional testing of multiple variants associated with bone mineral density in the FLNB gene region suggests that they represent a single association signal. *BMC Genetics*. https://www.semanticscholar.org/paper/8bb3e0fc7d487c8b0d82e807b0e07a7c14bf1780

[4] Bröcker, F., Bardenheuer, W., Vieten, L., Jülicher, K., Werner, N., Marquitan, G., Michael, D., Opalka, B., Schütte, J. (1999). Assignment of human filamin gene FLNB to human chromosome band 3p14.3 and identification of YACs containing the complete FLNB transcribed region. *Cytogenetic and Genome Research*. https://www.semanticscholar.org/paper/77d3c650681db1da04de94952d2cad9629751adf

[5] Arrigo, A., Rao, V. G., Ratan, A., Kulkarni, S. (2025). Patient-informed CRISPR Screen Identifies FLNB as a Novel Congenital Heart Disease and Ciliopathy Gene. *bioRxiv*. https://www.semanticscholar.org/paper/ec067f45f284481222926c8bcfd43c8d3055e061

[6] Veyssiere, M., Rodriguez Ordonez, M. d. P., Chalabi, S., Michou, L., Cornélis, F., Boland, A., Olaso, R., Deleuze, J., Petit-Teixeira, E., Chaudru, V. (2024). MYLK*FLNB and DOCK1*LAMA2 gene–gene interactions associated with rheumatoid arthritis in the focal adhesion pathway. *Frontiers in Genetics*. https://www.semanticscholar.org/paper/b55323b7f9759e57d494d16c96dda1539cf3963f

[7] Xu, Q., Cui, L., Lin, Y., Cui, L.-A. J., Xia, W. (2024). Disruption of FLNB leads to skeletal malformation by interfering with skeletal segmentation through the HOX gene. *Bone Reports*. https://www.semanticscholar.org/paper/ca4aa44c4b65cc9dadea0288ab1896641ea35312

[8] Farrington-Rock, C., Kirilova, V., Dillard-Telm, L., Borowsky, A., Chalk, S., Rock, M., Cohn, D., Krakow, D. (2007). Disruption of the Flnb gene in mice phenocopies the human disease spondylocarpotarsal synostosis syndrome. *Human Molecular Genetics*. https://www.semanticscholar.org/paper/812367ce2c9517b1bfb536166585c9bfa9c97a73

[9] Arrigo, A., Rao, V. G., Ratan, A., Kulkarni, S. S. (2026). Patient-informed CRISPR screen identifies FLNB as a congenital heart disease and ciliopathy gene. *HGG Advances*. https://www.semanticscholar.org/paper/fa6ca574b7d5063b99c1e2055e7d22f82360c01d

[10] Lam, A., Lai, K., Chan, D., Tong, T., Lam, S. (2006). Desbuquois Syndrome Atypical Hands Subtype with No Mutation in FLNB Gene. *Scientific Publication*. https://www.semanticscholar.org/paper/54e93b172db7e2c079daacef78c5547235bc2f6e

[11] Wilson, S. G., Mullin, B., Jones, M. R., Dick, I., Dudbridge, F., Spector, T., Prince, R. (2007). Variation in the FLNB gene regulates bone density in two populations of Caucasian women. *Scientific Publication*. https://www.semanticscholar.org/paper/a3f146c6a5f77af25420e87e3a4047ef28132d28

[12] Juul, T., Thomsen, L., Andreasen, C., Ejersted, C., Folkestad, L., Brusgaard, K., Hansen, S., Thomsen, J. S., Andersen, T., Frederiksen, A. L. (2025). Severe Osteoporosis in Larsen Syndrome—A Case Report of Bone Morphology and A Novel Filamin B (FLNB) Variant. *Calcified Tissue International*. https://www.semanticscholar.org/paper/963fddca6ae3516479bae8886f12b4e695eb03f2

[13] Bladen, J., Wang, J., Moosajee, M., Rahman, M., Sangaralingam, A., Gogna, V. K., Chelala, C., O’Toole, E. A., Philpott, M. (2025). GLI2 and FLNB Define Periocular Morphoeic Basal Cell Carcinoma. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/cd72e052a9f29aa2e7846668987783af3497182c

[14] Fan, G